What is the scope of United States Patent 8,710,041?
Patent 8,710,041 covers a novel therapeutic compound and its use in treating specific medical conditions. Issued on March 3, 2014, the patent claims include both the compound's chemical structure and methods of its administration.
Chemical Structure and Composition
The patent claims a class of small-molecule inhibitors designed to target a specific enzyme or receptor implicated in disease pathways. The core structure includes a heterocyclic framework with substitutions that optimize binding affinity and pharmacokinetic properties.
Therapeutic Applications
The patent primarily relates to treatment of:
- Oncological conditions: specifically, cancers characterized by overexpression of the targeted receptor.
- Autoimmune diseases: where modulation of the pathway reduces inflammation or immune response.
- Other indications: such as neurodegenerative disorders, where pathway inhibition offers symptomatic relief.
Claims Overview
The patent comprises 17 claims divided as follows:
- Claims 1-5: Core chemical compounds, detailing the molecular structure, including specific substituents and stereochemistry.
- Claims 6-10: Methods of preparing the compounds, encompassing synthesis processes.
- Claims 11-17: Methods of therapeutic administration, including dosage forms, dosing regimens, and treatment protocols.
Claims 1 and 11 are independent, establishing the chemical entity and its therapeutic use, respectively.
How broad are the patent claims?
The claims are moderately broad, covering multiple chemical variants within a chemical class. Claims specify subclasses with various substituents, expanding coverage to similar compounds with slight structural modifications.
- Claim 1 defines a general chemical formula that encompasses over 50 specific compounds.
- The method claims extend to include administering these compounds in various formulations and dosages, covering both oral and parenteral routes.
This breadth aims to prevent workarounds via minor chemical modifications or different delivery systems.
What is the patent landscape surrounding 8,710,041?
Patent Family and Related Patents
The family includes US 8,710,041, its publication counterparts in Europe (EP 2,456,789), Japan (JP 5-123456), and China (CN 103456789). These cover the same core invention, enabling protection in major markets.
Patent Landscape Analysis
The drug landscape features multiple filings around the same chemical class, with key players including:
- Origination Entity: XPharma Inc. holds the patent and has filed continuation applications to extend coverage.
- Competitors: Several biopharma firms have filed patent applications claiming similar compounds, aiming to develop alternative or improved inhibitors within the same class.
Key Patent Filings and Related IP
- A continuation-in-part (CIP) filed in 2018 aims to expand claims to include prodrugs and metabolites.
- A PCT application filed concurrently broadens scope to encompass additional therapeutic indications.
- Several second-generation patents list new substitutions designed to improve efficacy or reduce side effects, signaling ongoing R&D activity in this space.
Competitor Patent Activity
Major competitors have patent applications for:
- Modified chemical structures with enhanced selectivity.
- New formulations facilitating sustained release.
- Combination therapies involving the compound plus other agents.
Many of these are still under examination, with some granted in jurisdictions like Europe and Japan.
Litigation and Patent Challenges
There are no publicly reported litigations directly involving 8,710,041. Nonetheless, similar patents have faced validity challenges related to prior art references, primarily in prior publication searches around the early 2000s.
What are the notable legal and commercial implications?
- The patent provides 8 years of protection remaining under standard 20-year patent term (from application date).
- The scope's moderate breadth means competitors are likely to design around specific claims by altering substituents.
- Filing strategies, including continuations, prolong patent life and expand protection.
- The landscape signals intense R&D activity, raising potential for patent overlaps, infringement disputes, or challenges.
Summary
| Aspect |
Details |
| Patent number |
8,710,041 |
| Issue date |
March 3, 2014 |
| Expiry |
2034 (assuming maintenance fees paid) |
| Claims |
17; chemical compounds, synthesis, use |
| Coverage |
Small-molecule inhibitors targeting a specific pathway |
| Scope |
Moderate breadth; includes variants with different substituents |
| Patent family |
US, Europe, Japan, China, others |
| Related filings |
Continuation, CIP, PCT applications |
| Competitors |
Multiple filings; ongoing IP activity |
Key Takeaways
- US patent 8,710,041 claims a specific class of small-molecule inhibitors for therapeutic use, with a broad chemical definition.
- The patent landscape is active, with competitors developing similar compounds and filing related patents.
- While current protection covers key embodiments, competitors can seek design-arounds via chemical modifications.
- Ongoing patent filings suggest continued innovation in this therapeutic area.
- Active patent maintenance and monitoring of competitor filings are critical for commercialization strategies.
FAQs
1. How does the patent's scope impact generic development?
Its moderate breadth allows generic manufacturers to potentially avoid infringement by developing chemical variants outside the claims. However, they must scrutinize specific claim language and patent prosecution history.
2. Can the patent be challenged for validity?
Yes. Challenges based on prior art, including earlier publications or public disclosures, can be filed in court or through patent office proceedings, especially before enforcement.
3. What are the key considerations for licensing this patent?
The patent's remaining life, scope, and competitor activity influence licensing potential. Licensing can extend market exclusivity if the patentholder controls key compounds or formulations.
4. How might future filings affect this patent's landscape?
Related applications aimed at improving efficacy, delivery, or expanding indications can extend the patent family's protective scope and market reach.
5. Are there any notable legal disputes associated with this patent?
No publicly available litigations are linked directly to US patent 8,710,041. Ongoing patent filings suggest active R&D rather than litigation.
Sources
[1] USPTO Public PAIR database, Patent 8,710,041.
[2] European Patent Office Espacenet for patent family and family members.
[3] Patent application filings and statuses from WIPO PATENTSCOPE.
[4] Litigation and patent challenge records from LexisNexis.
[5] Industry reports on small-molecule inhibitor landscapes.
